{"protocolSection": {"identificationModule": {"nctId": "NCT00696436", "orgStudyIdInfo": {"id": "01-06-TL-491-019"}, "secondaryIdInfos": [{"id": "U1111-1113-9161", "type": "REGISTRY", "domain": "WHO"}], "organization": {"fullName": "Takeda", "class": "INDUSTRY"}, "briefTitle": "An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.", "officialTitle": "A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension"}, "statusModule": {"statusVerifiedDate": "2011-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-04"}, "primaryCompletionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-06-10", "studyFirstSubmitQcDate": "2008-06-10", "studyFirstPostDateStruct": {"date": "2008-06-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-03-24", "resultsFirstSubmitQcDate": "2011-03-24", "resultsFirstPostDateStruct": {"date": "2011-04-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-03-24", "lastUpdatePostDateStruct": {"date": "2011-04-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Sr. VP, Clinical Science", "oldOrganization": "Takeda Global Research & Development Center, Inc."}, "leadSponsor": {"name": "Takeda", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to placebo, valsartan and olmesartan in participants with essential hypertension.", "detailedDescription": "Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of antihypertensive treatments, hypertension remains inadequately controlled: only about one-third of patients successfully maintain control.\n\nA major component of blood pressure regulation is the renin-angiotensin-aldosterone system. This is a system of hormone-mediated feedback interactions that result in the relaxation or constriction of blood vessels in response to various stimuli. Angiotensin II, a polypeptide hormone, is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme as part of the renin-angiotensin-aldosterone system. Angiotensin II is the principal pressor agent of the renin-angiotensin-aldosterone system and has multiple effects on the cardiovascular system and on electrolyte homeostasis.\n\nTAK-491 (azilsartan medoxomil) is an angiotensin II type 1 receptor antagonist currently being tested as a treatment for essential hypertension.\n\nStudy participation is anticipated to be about 10 weeks. Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, physical examinations, electrocardiograms and ambulatory blood pressure monitoring. Outside of the study center, participants will be required wear an ambulatory blood pressure monitoring device at 24 hour intervals."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Essential Hypertension", "Cardiovascular Disease", "High Blood Pressure", "Drug Therapy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 1291, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Azilsartan Medoxomil 40 mg QD", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Azilsartan medoxomil"]}, {"label": "Azilsartan Medoxomil 80 mg QD", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Azilsartan medoxomil"]}, {"label": "Valsartan 320 mg QD", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Valsartan"]}, {"label": "Olmesartan 40 mg QD", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Olmesartan"]}, {"label": "Placebo QD", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Azilsartan medoxomil", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.", "armGroupLabels": ["Azilsartan Medoxomil 40 mg QD"], "otherNames": ["TAK-491", "Edarbi"]}, {"type": "DRUG", "name": "Azilsartan medoxomil", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.", "armGroupLabels": ["Azilsartan Medoxomil 80 mg QD"], "otherNames": ["TAK-491", "Edarbi"]}, {"type": "DRUG", "name": "Valsartan", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.", "armGroupLabels": ["Valsartan 320 mg QD"], "otherNames": ["Diovan\u00ae"]}, {"type": "DRUG", "name": "Olmesartan", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.", "armGroupLabels": ["Olmesartan 40 mg QD"], "otherNames": ["Benicar\u00ae"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo, orally, once daily for up to six weeks.", "armGroupLabels": ["Placebo QD"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.", "timeFrame": "Baseline and Week 6."}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.", "description": "The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.", "timeFrame": "Baseline and Week 6."}, {"measure": "Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.", "timeFrame": "Baseline and Week 6."}, {"measure": "Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure", "description": "The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.", "timeFrame": "Baseline and Week 6."}, {"measure": "Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.", "timeFrame": "Baseline and Week 6."}, {"measure": "Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.", "timeFrame": "Baseline and Week 6."}, {"measure": "Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.", "timeFrame": "Baseline and Week 6."}, {"measure": "Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.", "timeFrame": "Baseline and Week 6."}, {"measure": "Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.", "timeFrame": "Baseline and Week 6."}, {"measure": "Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.", "timeFrame": "Baseline and Week 6."}, {"measure": "Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.", "timeFrame": "Baseline and Week 6."}, {"measure": "Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.", "timeFrame": "Baseline and Week 6."}, {"measure": "Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline \u2265 20 mm Hg", "description": "Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.", "timeFrame": "Baseline and Week 6."}, {"measure": "Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline \u2265 10 mm Hg", "description": "Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.", "timeFrame": "Baseline and Week 6."}, {"measure": "Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response", "description": "Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.", "timeFrame": "Baseline and Week 6."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Essential hypertension (sitting systolic blood pressure between 150 and 180 mm Hg, inclusive, at Day -1 and 24-hour mean systolic blood pressure between 130 and 170 mm Hg, inclusive, at Day 1).\n2. Capable of understanding and complying with protocol requirements.\n3. Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study\n4. Clinical laboratory evaluations within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator.\n5. Willing to discontinue current antihypertensive medications at Screening Day 21 visit. If the participant is on amlodipine prior to Screening, the participant is willing to discontinue this medication at Screening Day -28.\n\nExclusion Criteria:\n\n1. Sitting diastolic blood pressure greater than 114 mm Hg at Day -1 (day prior to Randomization).\n2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.\n3. Taking or expected to take an excluded medication as described in the Excluded Medications.\n4. Hypersensitive to angiotensin II receptor blockers.\n5. History of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack.\n6. Clinically significant cardiac conduction defects.\n7. Hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.\n8. Secondary hypertension of any etiology.\n9. Noncompliant (less than 70% or greater than 130%) with study medication during run-in period.\n10. Moderate to severe renal dysfunction or disease.\n11. Known or suspected unilateral or bilateral renal artery stenosis.\n12. History of drug or alcohol abuse within the past 2 years.\n13. Previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. (This criterion does not apply to those participants with basal cell or stage I squamous cell carcinoma of the skin).\n14. Type 1 or poorly-controlled type 2 diabetes mellitus (glycosylate hemoglobin greater than 8.0%) at Screening.\n15. Hyperkalemia as defined by the central laboratory normal reference range at Screening.\n16. Alanine aminotransferase level of greater than 2.5 times the upper limit of normal, active liver disease, or jaundice at Screening.\n17. Upper arm circumference less than 24 cm or greater than 42 cm.\n18. Works night (3rd) shift (defined as 11 PM \\[2300\\] to 7 AM \\[0700\\]).\n19. Unwilling or unable to comply with the protocol or scheduled appointments.\n20. Currently is participating in another investigational study or has participated in an investigational study within 30 days prior to Randomization.\n21. Any other serious disease or condition at Screening or Randomization that would compromise participant's safety, might affect life expectancy, or make it difficult to successfully manage and follow the subject according to the protocol.\n22. Has been randomized in a previous azilsartan medoxomil study.\n23. Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Executive Medical Director Clinical Science", "affiliation": "Takeda", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Alabaster", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.24428, "lon": -86.81638}}, {"city": "Ozark", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 31.45906, "lon": -85.64049}}, {"city": "Green Valley", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 31.85425, "lon": -110.9937}}, {"city": "Litchfield Park", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.49337, "lon": -112.35794}}, {"city": "Mesa", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.42227, "lon": -111.82264}}, {"city": "Tempe", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.41477, "lon": -111.90931}}, {"city": "Carmichael", "state": "California", "country": "United States", "geoPoint": {"lat": 38.61713, "lon": -121.32828}}, {"city": "Chula Vista", "state": "California", "country": "United States", "geoPoint": {"lat": 32.64005, "lon": -117.0842}}, {"city": "Lincoln", "state": "California", "country": "United States", "geoPoint": {"lat": 38.89156, "lon": -121.29301}}, {"city": "Mission Viejo", "state": "California", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"city": "National City", "state": "California", "country": "United States", "geoPoint": {"lat": 32.67811, "lon": -117.0992}}, {"city": "Pasadena", "state": "California", "country": "United States", "geoPoint": {"lat": 34.14778, "lon": -118.14452}}, {"city": "Riverside", "state": "California", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"city": "Sacramento", "state": "California", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"city": "San Diego", "state": "California", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"city": "San Dimas", "state": "California", "country": "United States", "geoPoint": {"lat": 34.10668, "lon": -117.80673}}, {"city": "San Fransisco", "state": "California", "country": "United States", "geoPoint": {"lat": 37.77493, "lon": -122.41942}}, {"city": "San Ramon", "state": "California", "country": "United States", "geoPoint": {"lat": 37.77993, "lon": -121.97802}}, {"city": "Santa Ana", "state": "California", "country": "United States", "geoPoint": {"lat": 33.74557, "lon": -117.86783}}, {"city": "Vista", "state": "California", "country": "United States", "geoPoint": {"lat": 33.20004, "lon": -117.24254}}, {"city": "Colorado Springs", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"city": "Littleton", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.61332, "lon": -105.01665}}, {"city": "Longmont", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 40.16721, "lon": -105.10193}}, {"city": "Cape Coral", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.56285, "lon": -81.94953}}, {"city": "Clearwater", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"city": "Largo", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.90979, "lon": -82.78842}}, {"city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"city": "New Port Richey", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.24418, "lon": -82.71927}}, {"city": "New Smyrna Beach", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.02582, "lon": -80.927}}, {"city": "Palm Harbor", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.07807, "lon": -82.76371}}, {"city": "Tallahassee", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.43826, "lon": -84.28073}}, {"city": "Dunwoody", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.94621, "lon": -84.33465}}, {"city": "Roswell", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 34.02316, "lon": -84.36159}}, {"city": "Arlington Heights", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 42.08836, "lon": -87.98063}}, {"city": "Belleville", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 38.52005, "lon": -89.98399}}, {"city": "Champaign", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 40.11642, "lon": -88.24338}}, {"city": "Chicago", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"city": "Peoria", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 40.69365, "lon": -89.58899}}, {"city": "Vernon Hills", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 42.21947, "lon": -87.97952}}, {"city": "Evansville", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 37.97476, "lon": -87.55585}}, {"city": "Indianapolis", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"city": "Terre Haute", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 39.4667, "lon": -87.41391}}, {"city": "Kansas City", "state": "Kansas", "country": "United States", "geoPoint": {"lat": 39.11417, "lon": -94.62746}}, {"city": "Overland Park", "state": "Kansas", "country": "United States", "geoPoint": {"lat": 38.98223, "lon": -94.67079}}, {"city": "Shawnee", "state": "Kansas", "country": "United States", "geoPoint": {"lat": 39.04167, "lon": -94.72024}}, {"city": "Biddeford", "state": "Maine", "country": "United States", "geoPoint": {"lat": 43.49258, "lon": -70.45338}}, {"city": "Norwood", "state": "Maine", "country": "United States"}, {"city": "Baltimore", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"city": "Towson", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.4015, "lon": -76.60191}}, {"city": "Brooklyn Center", "state": "Minnesota", "country": "United States", "geoPoint": {"lat": 45.07608, "lon": -93.33273}}, {"city": "Chesterfield", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.66311, "lon": -90.57707}}, {"city": "Jefferson City", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.5767, "lon": -92.17352}}, {"city": "Kansas City", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"city": "St Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"city": "Billings", "state": "Montana", "country": "United States", "geoPoint": {"lat": 45.78329, "lon": -108.50069}}, {"city": "Las Vegas", "state": "Nevada", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"city": "Margate", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 39.32789, "lon": -74.50349}}, {"city": "Glens Falls", "state": "New York", "country": "United States", "geoPoint": {"lat": 43.30952, "lon": -73.64401}}, {"city": "Great Neck", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.80066, "lon": -73.72846}}, {"city": "New Hyde Park", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.7351, "lon": -73.68791}}, {"city": "New Windsor", "state": "New York", "country": "United States", "geoPoint": {"lat": 41.47676, "lon": -74.02375}}, {"city": "New York", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"city": "Charlotte", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"city": "Raleigh", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"city": "Columbus", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"city": "Norman", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.22257, "lon": -97.43948}}, {"city": "Tulsa", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"city": "Yukon", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.50672, "lon": -97.76254}}, {"city": "Ashland", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 42.19458, "lon": -122.70948}}, {"city": "Eugene", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"city": "Medford", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"city": "Portland", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"city": "Pittsburgh", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"city": "Tipton", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.6359, "lon": -78.29585}}, {"city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"city": "Murrells Inlet", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 33.551, "lon": -79.04143}}, {"city": "North Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.85462, "lon": -79.97481}}, {"city": "Cleveland", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 35.15952, "lon": -84.87661}}, {"city": "Bedford", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.84402, "lon": -97.14307}}, {"city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"city": "Missouri City", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.61857, "lon": -95.53772}}, {"city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"city": "Sugarland", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.61968, "lon": -95.63495}}, {"city": "Tacoma", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"city": "Carlos Paz", "state": "C\u00f3rdoba", "country": "Argentina"}, {"city": "Guaymayen", "state": "Mendoza", "country": "Argentina"}, {"city": "Bah\u00eda Blanca", "country": "Argentina", "geoPoint": {"lat": -38.71959, "lon": -62.27243}}, {"city": "Berazategui", "country": "Argentina", "geoPoint": {"lat": -34.76531, "lon": -58.21278}}, {"city": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"city": "Corrientes", "country": "Argentina", "geoPoint": {"lat": -27.4806, "lon": -58.8341}}, {"city": "C\u00f3rdoba", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"city": "Haedo Pcia. de Buenos Aires", "country": "Argentina"}, {"city": "Jujuy", "country": "Argentina"}, {"city": "La Plata", "country": "Argentina", "geoPoint": {"lat": -34.92145, "lon": -57.95453}}, {"city": "Ramos Mej\u00eda Pcia. de Buenos Aires", "country": "Argentina"}, {"city": "Rosario", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"city": "Salta", "country": "Argentina", "geoPoint": {"lat": -24.7859, "lon": -65.41166}}, {"city": "San Miguel de Tucum\u00e1n", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"city": "Belo Horizonte", "country": "Brazil", "geoPoint": {"lat": -19.92083, "lon": -43.93778}}, {"city": "Campinas", "country": "Brazil", "geoPoint": {"lat": -22.90556, "lon": -47.06083}}, {"city": "Fortaleza", "country": "Brazil", "geoPoint": {"lat": -3.71722, "lon": -38.54306}}, {"city": "Goiaenia", "country": "Brazil"}, {"city": "Joildille", "country": "Brazil"}, {"city": "Porto Alegre", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"city": "Rio Janeiro", "country": "Brazil"}, {"city": "Sao Paulo", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"city": "Sorocava", "country": "Brazil"}, {"city": "Tijuana", "state": "Baja California", "country": "Mexico", "geoPoint": {"lat": 32.5027, "lon": -117.00371}}, {"city": "Le\u00f3n", "state": "Guanajuato", "country": "Mexico", "geoPoint": {"lat": 21.12908, "lon": -101.67374}}, {"city": "Guadalajara", "state": "Jalapa", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"city": "Monterrey", "state": "Nuevo Leon", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"city": "Xalapa", "state": "Veracruz", "country": "Mexico", "geoPoint": {"lat": 19.53124, "lon": -96.91589}}, {"city": "Aguascalientes", "country": "Mexico", "geoPoint": {"lat": 21.88234, "lon": -102.28259}}, {"city": "Chihuahua", "country": "Mexico", "geoPoint": {"lat": 28.63528, "lon": -106.08889}}, {"city": "Mexico City", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"city": "Quer\u00e8taro", "country": "Mexico"}, {"city": "San Luis Potos\u00ed", "country": "Mexico", "geoPoint": {"lat": 22.14982, "lon": -100.97916}}, {"city": "Arequipa", "country": "Peru", "geoPoint": {"lat": -16.39889, "lon": -71.535}}, {"city": "Cusco", "country": "Peru", "geoPoint": {"lat": -13.52264, "lon": -71.96734}}, {"city": "Huaura", "country": "Peru", "geoPoint": {"lat": -11.07, "lon": -77.59944}}, {"city": "Ica", "country": "Peru", "geoPoint": {"lat": -14.06777, "lon": -75.72861}}, {"city": "Lima", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"city": "Trujillo", "country": "Peru", "geoPoint": {"lat": -8.11599, "lon": -79.02998}}, {"city": "Aguas Buenas", "country": "Puerto Rico", "geoPoint": {"lat": 18.2569, "lon": -66.10294}}, {"city": "Carolina", "country": "Puerto Rico", "geoPoint": {"lat": 18.38078, "lon": -65.95739}}, {"city": "Jardines de Loiza", "country": "Puerto Rico", "geoPoint": {"lat": 18.428, "lon": -65.87711}}, {"city": "Orocovis", "country": "Puerto Rico", "geoPoint": {"lat": 18.2269, "lon": -66.391}}, {"city": "Ponce", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"city": "San Juan", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}]}, "referencesModule": {"references": [{"pmid": "21282560", "type": "RESULT", "citation": "White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar;57(3):413-20. doi: 10.1161/HYPERTENSIONAHA.110.163402. Epub 2011 Jan 31."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants with essential hypertension were enrolled in one of five, once-daily (QD) treatment groups.", "recruitmentDetails": "Participants enrolled at 141 investigative sites in Guatemala, Mexico, Peru, Puerto Rico and the United States from 02 April 2008 to 19 August 2009.", "groups": [{"id": "FG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "FG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "FG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "FG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "FG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Randomized participants only.", "numSubjects": "280"}, {"groupId": "FG001", "comment": "Randomized participants only. One participant treated but not randomized and is not included.", "numSubjects": "285"}, {"groupId": "FG002", "comment": "Randomized participants only.", "numSubjects": "282"}, {"groupId": "FG003", "comment": "Randomized participants only.", "numSubjects": "290"}, {"groupId": "FG004", "comment": "Randomized participants only.", "numSubjects": "154"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "257"}, {"groupId": "FG001", "numSubjects": "255"}, {"groupId": "FG002", "numSubjects": "254"}, {"groupId": "FG003", "numSubjects": "268"}, {"groupId": "FG004", "numSubjects": "141"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "23"}, {"groupId": "FG001", "numSubjects": "30"}, {"groupId": "FG002", "numSubjects": "28"}, {"groupId": "FG003", "numSubjects": "22"}, {"groupId": "FG004", "numSubjects": "13"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "6"}, {"groupId": "FG004", "numSubjects": "4"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "4"}]}, {"type": "Participant Unavailability", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Administrative Error", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Participant Non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Administrative Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Missing", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "BG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "BG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "BG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "BG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "280"}, {"groupId": "BG001", "value": "285"}, {"groupId": "BG002", "value": "282"}, {"groupId": "BG003", "value": "290"}, {"groupId": "BG004", "value": "154"}, {"groupId": "BG005", "value": "1291"}]}], "measures": [{"title": "Age Categorical", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<45 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "38"}, {"groupId": "BG002", "value": "56"}, {"groupId": "BG003", "value": "39"}, {"groupId": "BG004", "value": "20"}, {"groupId": "BG005", "value": "194"}]}]}, {"title": "Between 45 and 64 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "170"}, {"groupId": "BG001", "value": "184"}, {"groupId": "BG002", "value": "178"}, {"groupId": "BG003", "value": "185"}, {"groupId": "BG004", "value": "98"}, {"groupId": "BG005", "value": "815"}]}]}, {"title": "\u226565 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "69"}, {"groupId": "BG001", "value": "63"}, {"groupId": "BG002", "value": "48"}, {"groupId": "BG003", "value": "66"}, {"groupId": "BG004", "value": "36"}, {"groupId": "BG005", "value": "282"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "133"}, {"groupId": "BG001", "value": "134"}, {"groupId": "BG002", "value": "130"}, {"groupId": "BG003", "value": "131"}, {"groupId": "BG004", "value": "64"}, {"groupId": "BG005", "value": "592"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "147"}, {"groupId": "BG001", "value": "151"}, {"groupId": "BG002", "value": "152"}, {"groupId": "BG003", "value": "159"}, {"groupId": "BG004", "value": "90"}, {"groupId": "BG005", "value": "699"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.", "populationDescription": "Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 6.", "groups": [{"id": "OG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "237"}, {"groupId": "OG001", "value": "229"}, {"groupId": "OG002", "value": "234"}, {"groupId": "OG003", "value": "254"}, {"groupId": "OG004", "value": "134"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.42", "spread": "0.690"}, {"groupId": "OG001", "value": "-14.53", "spread": "0.702"}, {"groupId": "OG002", "value": "-10.22", "spread": "0.696"}, {"groupId": "OG003", "value": "-11.99", "spread": "0.666"}, {"groupId": "OG004", "value": "-0.25", "spread": "0.917"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-14.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.54", "ciUpperLimit": "-12.01"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-13.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-15.41", "ciUpperLimit": "-10.91"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.009", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.54", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.44", "ciUpperLimit": "-0.64"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-4.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.25", "ciUpperLimit": "-2.37"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.136", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.43", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.31", "ciUpperLimit": "0.45"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.20", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.12", "ciUpperLimit": "-1.27"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.", "description": "The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.", "populationDescription": "Full analysis set with last observation carried forward.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 6.", "groups": [{"id": "OG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "271"}, {"groupId": "OG003", "value": "283"}, {"groupId": "OG004", "value": "148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-16.38", "spread": "0.959"}, {"groupId": "OG001", "value": "-16.74", "spread": "0.957"}, {"groupId": "OG002", "value": "-11.31", "spread": "0.955"}, {"groupId": "OG003", "value": "-13.20", "spread": "0.935"}, {"groupId": "OG004", "value": "-1.83", "spread": "1.293"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-14.92", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-18.07", "ciUpperLimit": "-11.76"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-14.55", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.71", "ciUpperLimit": "-11.40"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.008", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.54", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.17", "ciUpperLimit": "-0.92"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-5.43", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.09", "ciUpperLimit": "-2.78"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.018", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.81", "ciUpperLimit": "-0.55"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-5.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.73", "ciUpperLimit": "-2.42"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.", "populationDescription": "Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 6.", "groups": [{"id": "OG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "237"}, {"groupId": "OG001", "value": "229"}, {"groupId": "OG002", "value": "234"}, {"groupId": "OG003", "value": "254"}, {"groupId": "OG004", "value": "134"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.65", "spread": "0.472"}, {"groupId": "OG001", "value": "-9.43", "spread": "0.480"}, {"groupId": "OG002", "value": "-7.09", "spread": "0.476"}, {"groupId": "OG003", "value": "-7.74", "spread": "0.456"}, {"groupId": "OG004", "value": "-0.07", "spread": "0.627"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-9.36", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.91", "ciUpperLimit": "-7.81"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-8.58", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.12", "ciUpperLimit": "-7.04"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.011", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.99", "ciUpperLimit": "-0.40"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.35", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.67", "ciUpperLimit": "-1.02"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.166", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.91", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.19", "ciUpperLimit": "0.38"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.020", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.56", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.88", "ciUpperLimit": "-0.24"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure", "description": "The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.", "populationDescription": "Full analysis set with last observation carried forward.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 6.", "groups": [{"id": "OG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "271"}, {"groupId": "OG003", "value": "283"}, {"groupId": "OG004", "value": "148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.97", "spread": "0.552"}, {"groupId": "OG001", "value": "-8.27", "spread": "0.551"}, {"groupId": "OG002", "value": "-5.11", "spread": "0.550"}, {"groupId": "OG003", "value": "-6.10", "spread": "0.538"}, {"groupId": "OG004", "value": "-0.76", "spread": "0.744"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-7.51", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.33", "ciUpperLimit": "-5.69"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.03", "ciUpperLimit": "-4.39"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.005", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.69", "ciUpperLimit": "-0.67"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.69", "ciUpperLimit": "-1.64"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.257", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.87", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.39", "ciUpperLimit": "0.64"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.017", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.39", "ciUpperLimit": "-0.33"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.", "populationDescription": "Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 6.", "groups": [{"id": "OG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "237"}, {"groupId": "OG001", "value": "229"}, {"groupId": "OG002", "value": "234"}, {"groupId": "OG003", "value": "254"}, {"groupId": "OG004", "value": "134"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.73", "spread": "0.724"}, {"groupId": "OG001", "value": "-15.02", "spread": "0.736"}, {"groupId": "OG002", "value": "-10.26", "spread": "0.730"}, {"groupId": "OG003", "value": "-12.16", "spread": "0.699"}, {"groupId": "OG004", "value": "-0.11", "spread": "0.963"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-14.92", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.30", "ciUpperLimit": "-12.54"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-13.63", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-15.99", "ciUpperLimit": "-11.27"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.005", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.85", "ciUpperLimit": "-0.87"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-4.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.80", "ciUpperLimit": "-2.73"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.119", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.57", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.55", "ciUpperLimit": "0.40"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.47", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.49", "ciUpperLimit": "-1.45"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.", "populationDescription": "Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 6.", "groups": [{"id": "OG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "237"}, {"groupId": "OG001", "value": "229"}, {"groupId": "OG002", "value": "234"}, {"groupId": "OG003", "value": "254"}, {"groupId": "OG004", "value": "134"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.96", "spread": "0.510"}, {"groupId": "OG001", "value": "-9.80", "spread": "0.518"}, {"groupId": "OG002", "value": "-7.23", "spread": "0.514"}, {"groupId": "OG003", "value": "-7.82", "spread": "0.492"}, {"groupId": "OG004", "value": "0.01", "spread": "0.677"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-9.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.48", "ciUpperLimit": "-8.13"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-8.96", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.63", "ciUpperLimit": "-7.30"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.006", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.39", "ciUpperLimit": "-0.58"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.57", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.00", "ciUpperLimit": "-1.14"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.107", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.53", "ciUpperLimit": "0.25"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.017", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.73", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.15", "ciUpperLimit": "-0.30"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.", "populationDescription": "Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 6.", "groups": [{"id": "OG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "237"}, {"groupId": "OG001", "value": "229"}, {"groupId": "OG002", "value": "234"}, {"groupId": "OG003", "value": "254"}, {"groupId": "OG004", "value": "134"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.28", "spread": "0.778"}, {"groupId": "OG001", "value": "-13.32", "spread": "0.792"}, {"groupId": "OG002", "value": "-9.66", "spread": "0.784"}, {"groupId": "OG003", "value": "-11.90", "spread": "0.752"}, {"groupId": "OG004", "value": "-0.31", "spread": "1.035"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-13.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-15.56", "ciUpperLimit": "-10.45"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-11.97", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.51", "ciUpperLimit": "-9.43"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.194", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.42", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.56", "ciUpperLimit": "0.72"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.84", "ciUpperLimit": "-1.46"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.720", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.51", "ciUpperLimit": "1.73"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.018", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.62", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.79", "ciUpperLimit": "-0.45"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.", "populationDescription": "Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 6.", "groups": [{"id": "OG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "237"}, {"groupId": "OG001", "value": "229"}, {"groupId": "OG002", "value": "234"}, {"groupId": "OG003", "value": "254"}, {"groupId": "OG004", "value": "134"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.65", "spread": "0.540"}, {"groupId": "OG001", "value": "-8.54", "spread": "0.550"}, {"groupId": "OG002", "value": "-6.26", "spread": "0.544"}, {"groupId": "OG003", "value": "-7.82", "spread": "0.522"}, {"groupId": "OG004", "value": "0.10", "spread": "0.718"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-8.64", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.42", "ciUpperLimit": "-6.87"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-7.75", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.52", "ciUpperLimit": "-5.99"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.341", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.72", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.21", "ciUpperLimit": "0.77"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.003", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.80", "ciUpperLimit": "-0.76"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.821", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.30", "ciUpperLimit": "1.64"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.071", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.89", "ciUpperLimit": "0.12"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.", "populationDescription": "Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 6.", "groups": [{"id": "OG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "237"}, {"groupId": "OG001", "value": "229"}, {"groupId": "OG002", "value": "234"}, {"groupId": "OG003", "value": "254"}, {"groupId": "OG004", "value": "134"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-14.03", "spread": "0.764"}, {"groupId": "OG001", "value": "-15.55", "spread": "0.777"}, {"groupId": "OG002", "value": "-10.44", "spread": "0.770"}, {"groupId": "OG003", "value": "-12.23", "spread": "0.738"}, {"groupId": "OG004", "value": "-0.10", "spread": "1.016"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-15.45", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.96", "ciUpperLimit": "-12.94"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-13.93", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.42", "ciUpperLimit": "-11.43"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.42", "ciUpperLimit": "-1.22"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-5.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.26", "ciUpperLimit": "-2.97"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.091", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.80", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.88", "ciUpperLimit": "0.29"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.72", "ciUpperLimit": "-1.46"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.", "populationDescription": "Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 6.", "groups": [{"id": "OG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "237"}, {"groupId": "OG001", "value": "229"}, {"groupId": "OG002", "value": "234"}, {"groupId": "OG003", "value": "254"}, {"groupId": "OG004", "value": "134"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.16", "spread": "0.542"}, {"groupId": "OG001", "value": "-10.13", "spread": "0.551"}, {"groupId": "OG002", "value": "-7.42", "spread": "0.547"}, {"groupId": "OG003", "value": "-7.82", "spread": "0.524"}, {"groupId": "OG004", "value": "0.01", "spread": "0.721"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-10.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.92", "ciUpperLimit": "-8.36"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-9.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.94", "ciUpperLimit": "-7.40"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.81", "ciUpperLimit": "-0.82"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.71", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.24", "ciUpperLimit": "-1.19"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.076", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.34", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.82", "ciUpperLimit": "0.14"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.024", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.74", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.25", "ciUpperLimit": "-0.22"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.", "populationDescription": "Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 6.", "groups": [{"id": "OG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "236"}, {"groupId": "OG001", "value": "229"}, {"groupId": "OG002", "value": "234"}, {"groupId": "OG003", "value": "254"}, {"groupId": "OG004", "value": "134"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.46", "spread": "0.860"}, {"groupId": "OG001", "value": "-13.38", "spread": "0.873"}, {"groupId": "OG002", "value": "-9.14", "spread": "0.865"}, {"groupId": "OG003", "value": "-11.65", "spread": "0.829"}, {"groupId": "OG004", "value": "-0.55", "spread": "1.142"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-12.84", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-15.66", "ciUpperLimit": "-10.02"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-11.91", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.72", "ciUpperLimit": "-9.11"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.149", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.74", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.10", "ciUpperLimit": "0.62"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-4.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.65", "ciUpperLimit": "-1.83"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.494", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.82", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.16", "ciUpperLimit": "1.53"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.007", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.72", "ciUpperLimit": "-0.93"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.", "description": "The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.", "populationDescription": "Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 6.", "groups": [{"id": "OG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "236"}, {"groupId": "OG001", "value": "229"}, {"groupId": "OG002", "value": "234"}, {"groupId": "OG003", "value": "254"}, {"groupId": "OG004", "value": "134"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.69", "spread": "0.648"}, {"groupId": "OG001", "value": "-8.61", "spread": "0.657"}, {"groupId": "OG002", "value": "-6.22", "spread": "0.651"}, {"groupId": "OG003", "value": "-8.25", "spread": "0.624"}, {"groupId": "OG004", "value": "-0.69", "spread": "0.859"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-7.91", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.03", "ciUpperLimit": "-5.79"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-7.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.10", "ciUpperLimit": "-5.88"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.691", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.36", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.14", "ciUpperLimit": "1.42"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.010", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.20", "ciUpperLimit": "-0.57"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.625", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.44", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.20", "ciUpperLimit": "1.32"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.008", "pValueComment": "Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.27", "ciUpperLimit": "-0.66"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline \u2265 20 mm Hg", "description": "Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.", "populationDescription": "Full analysis set with last observation carried forward.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and Week 6.", "groups": [{"id": "OG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "271"}, {"groupId": "OG003", "value": "283"}, {"groupId": "OG004", "value": "148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "56.5"}, {"groupId": "OG001", "value": "57.8"}, {"groupId": "OG002", "value": "48.7"}, {"groupId": "OG003", "value": "48.8"}, {"groupId": "OG004", "value": "22.3"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "4.98", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.15", "ciUpperLimit": "7.88"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "4.66", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.94", "ciUpperLimit": "7.37"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.032", "pValueComment": "P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.45", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.03", "ciUpperLimit": "2.03"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.029", "pValueComment": "P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.04", "ciUpperLimit": "2.06"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.080", "pValueComment": "P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.35", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.96", "ciUpperLimit": "1.89"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.071", "pValueComment": "P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.97", "ciUpperLimit": "1.92"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline \u2265 10 mm Hg", "description": "Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.", "populationDescription": "Full analysis set with last observation carried forward.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and Week 6.", "groups": [{"id": "OG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "271"}, {"groupId": "OG003", "value": "283"}, {"groupId": "OG004", "value": "148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "68.8"}, {"groupId": "OG001", "value": "71.1"}, {"groupId": "OG002", "value": "63.8"}, {"groupId": "OG003", "value": "68.2"}, {"groupId": "OG004", "value": "43.9"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "3.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.10", "ciUpperLimit": "5.15"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "2.91", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.86", "ciUpperLimit": "4.54"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.306", "pValueComment": "P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.22", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.83", "ciUpperLimit": "1.80"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.132", "pValueComment": "P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.34", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.92", "ciUpperLimit": "1.97"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.695", "pValueComment": "P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.74", "ciUpperLimit": "1.58"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.381", "pValueComment": "P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.81", "ciUpperLimit": "1.74"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response", "description": "Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.", "populationDescription": "Full analysis set with last observation carried forward.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and Week 6.", "groups": [{"id": "OG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."}, {"id": "OG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."}, {"id": "OG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "271"}, {"groupId": "OG003", "value": "283"}, {"groupId": "OG004", "value": "148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "49.1"}, {"groupId": "OG001", "value": "52.6"}, {"groupId": "OG002", "value": "43.9"}, {"groupId": "OG003", "value": "44.5"}, {"groupId": "OG004", "value": "18.2"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "5.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.20", "ciUpperLimit": "8.41"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "4.43", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.73", "ciUpperLimit": "7.19"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.056", "pValueComment": "P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.99", "ciUpperLimit": "1.94"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.036", "pValueComment": "P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.44", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.02", "ciUpperLimit": "2.02"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.317", "pValueComment": "P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.85", "ciUpperLimit": "1.66"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.234", "pValueComment": "P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.87", "ciUpperLimit": "1.73"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.", "description": "At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.", "eventGroups": [{"id": "EG000", "title": "Azilsartan Medoxomil 40 mg QD", "description": "Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.\n\nIncreased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.", "seriousNumAffected": 2, "seriousNumAtRisk": 280, "otherNumAffected": 18, "otherNumAtRisk": 280}, {"id": "EG001", "title": "Azilsartan Medoxomil 80 mg QD", "description": "Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.", "seriousNumAffected": 3, "seriousNumAtRisk": 284, "otherNumAffected": 12, "otherNumAtRisk": 284}, {"id": "EG002", "title": "Valsartan 320 mg QD", "description": "Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.\n\nIncreased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.", "seriousNumAffected": 3, "seriousNumAtRisk": 277, "otherNumAffected": 21, "otherNumAtRisk": 277}, {"id": "EG003", "title": "Olmesartan 40 mg QD", "description": "Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.\n\nIncreased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.", "seriousNumAffected": 4, "seriousNumAtRisk": 290, "otherNumAffected": 23, "otherNumAtRisk": 290}, {"id": "EG004", "title": "Placebo QD", "description": "Matching placebo, orally, once daily for up to six weeks.", "seriousNumAffected": 2, "seriousNumAtRisk": 155, "otherNumAffected": 14, "otherNumAtRisk": 155}], "seriousEvents": [{"term": "Eye irritation", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 155}]}, {"term": "Abdominal adhesions", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 155}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 155}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 155}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 155}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 155}]}, {"term": "Infected bites", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 155}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 155}]}, {"term": "Intentional overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 155}]}, {"term": "Subdural haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 155}]}, {"term": "Blood pressure increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 155}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 155}]}, {"term": "Partial seizures", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 155}]}, {"term": "Dysfunctional uterine bleeding", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 155}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 155}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 155}]}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 280}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 284}, {"groupId": "EG002", "numAffected": 21, "numAtRisk": 277}, {"groupId": "EG003", "numAffected": 23, "numAtRisk": 290}, {"groupId": "EG004", "numAffected": 14, "numAtRisk": 155}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property."}, "pointOfContact": {"title": "Sr. VP, Clinical Science", "organization": "Takeda Global Research and Development Center, Inc.", "email": "clinicaltrialregistry@tpna.com", "phone": "800-778-2860"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068756", "term": "Valsartan"}, {"id": "C000437965", "term": "Olmesartan"}, {"id": "C000557413", "term": "Azilsartan medoxomil"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M256876", "name": "Azilsartan medoxomil", "asFound": "Both sides", "relevance": "HIGH"}, {"id": "M91890", "name": "Olmesartan", "asFound": "Anticoagulation", "relevance": "HIGH"}, {"id": "M273", "name": "Olmesartan Medoxomil", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}